Beryl Drugs Ltd
Incorporated in 1993, Beryl Drugs Ltd
is in the business of pharmaceuticals manufacturing[1]
- Market Cap ₹ 10.3 Cr.
- Current Price ₹ 20.3
- High / Low ₹ 46.0 / 17.4
- Stock P/E 44.7
- Book Value ₹ 18.7
- Dividend Yield 0.00 %
- ROCE 10.1 %
- ROE 6.30 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.08 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 26.4%
- Company has a low return on equity of 8.32% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
14.54 | 13.23 | 12.99 | 10.90 | 15.08 | 12.81 | 12.78 | 14.03 | 14.48 | 26.84 | 26.72 | 22.56 | 21.09 | |
13.77 | 12.50 | 12.49 | 10.96 | 14.04 | 11.78 | 11.87 | 12.58 | 14.04 | 24.84 | 24.36 | 19.92 | 18.89 | |
Operating Profit | 0.77 | 0.73 | 0.50 | -0.06 | 1.04 | 1.03 | 0.91 | 1.45 | 0.44 | 2.00 | 2.36 | 2.64 | 2.20 |
OPM % | 5.30% | 5.52% | 3.85% | -0.55% | 6.90% | 8.04% | 7.12% | 10.33% | 3.04% | 7.45% | 8.83% | 11.70% | 10.43% |
0.18 | 0.18 | 0.37 | 0.27 | 0.69 | 0.24 | 0.23 | 0.64 | 0.16 | 0.27 | 0.40 | 0.00 | 0.00 | |
Interest | 0.20 | 0.26 | 0.21 | 0.20 | 0.13 | 0.15 | 0.32 | 0.47 | 0.46 | 0.47 | 0.55 | 0.53 | 0.42 |
Depreciation | 0.32 | 0.52 | 0.41 | 0.38 | 0.33 | 0.32 | 0.66 | 1.27 | 1.09 | 0.81 | 1.20 | 1.25 | 1.34 |
Profit before tax | 0.43 | 0.13 | 0.25 | -0.37 | 1.27 | 0.80 | 0.16 | 0.35 | -0.95 | 0.99 | 1.01 | 0.86 | 0.44 |
Tax % | 37.21% | 38.46% | 32.00% | 18.92% | 22.05% | 26.25% | 68.75% | 31.43% | -30.53% | 22.22% | 23.76% | 33.72% | |
0.27 | 0.08 | 0.17 | -0.45 | 0.99 | 0.59 | 0.05 | 0.24 | -0.66 | 0.77 | 0.77 | 0.58 | 0.23 | |
EPS in Rs | 0.53 | 0.16 | 0.34 | -0.89 | 1.95 | 1.16 | 0.10 | 0.47 | -1.30 | 1.52 | 1.52 | 1.14 | 0.46 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 5% |
5 Years: | 12% |
3 Years: | 16% |
TTM: | -16% |
Compounded Profit Growth | |
---|---|
10 Years: | 22% |
5 Years: | 63% |
3 Years: | 42% |
TTM: | -62% |
Stock Price CAGR | |
---|---|
10 Years: | -6% |
5 Years: | 21% |
3 Years: | 27% |
1 Year: | -30% |
Return on Equity | |
---|---|
10 Years: | 3% |
5 Years: | 3% |
3 Years: | 8% |
Last Year: | 6% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 |
Reserves | 1.33 | 1.40 | 1.57 | 0.79 | 1.57 | 2.43 | 2.53 | 2.84 | 2.20 | 2.97 | 3.83 | 4.41 |
1.53 | 1.72 | 1.69 | 1.72 | 1.48 | 3.25 | 5.23 | 5.12 | 5.29 | 4.54 | 5.09 | 4.08 | |
1.79 | 2.71 | 1.80 | 2.85 | 2.69 | 3.80 | 4.07 | 5.60 | 5.25 | 4.92 | 3.48 | 2.38 | |
Total Liabilities | 9.74 | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 | 15.96 |
2.79 | 2.43 | 2.44 | 2.25 | 2.22 | 1.96 | 8.60 | 7.52 | 6.04 | 6.03 | 6.17 | 6.20 | |
CWIP | 0.13 | 0.24 | 0.00 | 0.00 | 0.08 | 6.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.73 | 0.68 | 0.68 | 0.49 | 0.22 | 0.48 | 0.56 | 0.12 | 0.16 | 0.15 | 0.00 | 0.00 |
6.09 | 7.57 | 7.03 | 7.71 | 8.31 | 5.89 | 7.76 | 11.01 | 11.63 | 11.34 | 11.32 | 9.76 | |
Total Assets | 9.74 | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 | 15.96 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.70 | -0.13 | 0.37 | -0.10 | 3.35 | 0.18 | 0.34 | -0.47 | 2.48 | 0.82 | 2.64 | |
0.00 | 0.02 | 0.17 | 0.32 | -0.03 | -5.01 | -1.55 | 0.26 | 0.52 | -1.30 | -1.08 | -0.40 | |
0.00 | -0.09 | -0.23 | -0.19 | -0.36 | 1.62 | 1.67 | -0.54 | -0.24 | -1.17 | 0.10 | -1.55 | |
Net Cash Flow | 0.00 | 0.63 | -0.19 | 0.50 | -0.49 | -0.04 | 0.30 | 0.06 | -0.18 | 0.01 | -0.16 | 0.69 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 64.26 | 102.08 | 100.59 | 102.47 | 116.91 | 98.02 | 98.53 | 118.11 | 112.17 | 93.83 | 103.54 | 88.34 |
Inventory Days | 52.84 | 64.34 | 65.28 | 151.29 | 53.10 | 39.74 | 486.67 | 1,135.00 | 245.67 | 64.33 | ||
Days Payable | 50.59 | 69.91 | 34.34 | 65.24 | 57.03 | 93.60 | 755.17 | 1,110.00 | 758.08 | 37.92 | ||
Cash Conversion Cycle | 66.51 | 96.50 | 131.54 | 188.52 | 112.97 | 44.16 | -169.97 | 143.11 | 112.17 | -418.57 | 103.54 | 114.75 |
Working Capital Days | 36.90 | 38.35 | 58.44 | 67.31 | 71.89 | -6.55 | 13.99 | 38.76 | 63.52 | 46.51 | 57.92 | 63.58 |
ROCE % | 8.42% | 5.20% | 5.56% | -2.26% | 11.94% | 9.94% | 4.06% | 2.86% | -3.82% | 11.60% | 11.65% | 10.08% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Aug - NEWSPAPER PUBLICATION OF UNAUDITED RESULTS FOR THE QUARTER ENDED 30.06.2025
- UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025 7 Aug
-
Board Meeting Outcome for OUTCOME OF BOARD MEETING
7 Aug - Approved Q1 FY2025-26 unaudited financial results and auditor's limited review report.
-
Board Meeting Intimation for Consider And Approve The Unaudited Financial Results For The Quarter Ended 30Th June, 2025
29 Jul - Board meeting on 7 Aug 2025 to approve Q1 FY26 unaudited financial results.
-
Compliance-57 (5) : intimation after the end of quarter
5 Jul - No non-convertible securities interest/dividend payable for quarter ended 30.06.2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
BDL is mainly engaged in the domestic, institutions, and export supply of bulk drugs, pharmaceuticals, and healthcare products
like I.V. Fluids and Small Volume Injectables.
It manufactures and markets a range of branded, generic pharmaceutical formulations through its nationwide sales and distribution network and provides research and development, contract manufacturing services, and veterinary products.